See other companies on Welcome to the Jungle
CoSyne Therapeutics
Drug discovery company
- 1-20 employees
- Healthcare
- B2B
- Biotechnology
- MedTech
- Soho, London, UK
Jump to section
Company mission
To create new treatments to help patients. Everything else is secondary.
50% female employees
Our take
On a mission to break down barriers between the technology industry and the biological industry in order to push the limits of science, computing and artificial intelligence, Cosyne Therapeutics is a computational drug discovery company that uses genetics and computational systems to develop next-generation medicines.
In its early stages, Cosyne’s primary goal is to build a new class of drugs to treat Glioblastoma Multiforme, which is considered the most deadly form of human brain cancer. It is well placed to do this, as its platform enables the identification of vulnerabilities in cells that no other institution has done before.
The company recently closed a significant seed-funding round from industry-leading investors, which is being used to expand the scope of its functional genomics and machine learning capabilities.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Generous Equity Scheme
- Flexible Working Style
- Enhanced parental leave for primary and secondary caregiver
- More Benefits to come after Series A (We want you to help us design the benefits that work best for you)
Company values
- Patients First - Every decision is framed by one question: “What is in the best interests of the patients?”. We try to understand their needs and walk beside them through their diagnoses and treatments. We understand their problems first-hand and we are best placed to solve them. When we generate value for our patients, all other metrics will follow
- Fearlessness - We are not afraid to tackle the hardest problems. If we fear failure, we create an environment that only allows for incremental improvements. Instead, we understand that moon shots are achieved by breaking through failures and learning from them. It is not enough to only see the problems in science - real scientific creativity lies in finding the path through those problems to new possibilities
- Urgency - The pace of clinical translation is paramount. Every day, patients are dying from diseases. We owe it to these patients and their families to work quickly
- Integrity - We are all held to the highest standards, starting with non-maleficence (first do no harm), beneficence, justice, and autonomy. We apply these standards to all activities regardless of the situation. While some of the best minds of our generation have been distracted designing addictive technologies and encouraging consumers to click adverts, we are bringing focus back to the most worthwhile endeavours for humanity, like treating the most devastating diseases
- Collaboration - Diseases can be cured by combining technology and tools from seemingly unrelated domains. By breaking down silos, we bring together experts who would otherwise rarely interact to solve some of humanities greatest challenges. It is at these intersections between disciplines that the greatest innovations are born
Funding (1 round)
Jan 2022
$0.5m
GRANT
Total funding: $0.5m
This company has top investors
Leadership
Liisi Laaniste
(CSO & Founder)Previously spent time as a Post-Doctoral Researcher for Imperial College London and as a Junior Researcher for Uppsala University.
Louwai Muhammed
(CEO & Founder)Previously spent over eight years at the NHS, initially as an Academic Foundation Doctor, and later as a Neurology Registrar.
Michael Johnson
(CMO & Founder)Professor of Neurology and Genomic Medicine.
Diversity, Equity & Inclusion at CoSyne Therapeutics
- We are a multinational team with 7 nationalities in our team of 12